JACC: Cardiooncology

Papers
(The TQCC of JACC: Cardiooncology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Full Issue PDF135
Priorities in Cardio-Oncology132
Balancing Promise and Evidence115
Hormonal Therapy and Cardiovascular Health102
Full Issue PDF94
Epigenomics of Cardio-Oncology81
Atrial Fibrillation in Patients With Cancer76
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque76
Full Issue PDF72
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy66
Editorial Board65
Cardiovascular Safety in Oncology Clinical Trials61
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients61
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors60
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy59
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part56
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes56
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors55
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD51
Full Issue PDF51
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms48
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis45
Frailty42
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA42
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy41
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients40
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma39
Cardiac Risk Stratification Before Lung Cancer Radiation39
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy36
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)36
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD33
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis33
Editorial Board/Officers Page33
Clonal Hematopoiesis in Cancer and Cardiovascular Disease32
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer32
Permissive Cardiotoxicity31
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance29
Cancer Immunotherapy Beyond Checkpoint Blockade28
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients27
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors27
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-201927
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation26
Leveling Up26
Full Issue PDF26
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy26
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO25
Editorial Board25
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS25
Developing a Model for Cross-Institutional Educational Collaborations25
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research24
Reply24
Endothelin-124
Quality-of-Care Measures for Cardio-Oncology23
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity23
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity23
Vascular Complications of Atrial Fibrillation in Patients With Cancer22
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK22
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge22
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity22
CHA2DS2-VASc Score in Cardio-Oncology22
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy22
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction22
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer22
Fluoropyrimidine Therapy in Gastrointestinal Cancer21
Full Issue PDF21
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients21
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity21
Diet and Prevention of Cardiovascular Disease and Cancer20
High-Sensitivity Troponin I19
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.18
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy18
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction18
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer18
Low QRS Voltages in Cardiac Amyloidosis18
Imaging Immune Checkpoint Inhibitor Myocarditis18
The United Kingdom’s First Cardio-Oncology Service18
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction18
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia17
FULL ISSUE PDF17
Cardiovascular Risk Assessment in Patients With Kidney Cancer17
To Adjudicate or Not Adjudicate17
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity17
Cancer Therapy–Related Cardiac Dysfunction16
ABSTRACT WITHDRAWN15
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors15
Full Issue PDF15
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer15
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING15
Author Index15
Hearts on the Minds of Oncologists15
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy14
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?14
Full Issue PDF14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors14
Navigating the Uncharted13
Cardiovascular Considerations After Cancer Therapy13
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors13
Cardiovascular Care After Cancer13
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness13
(Less) Time and Energy13
Guiding Treatment With Recovered CTRCD13
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?13
Preventing Cancer Therapy–Related Cardiotoxicity12
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction12
Reply12
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer11
Reply11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA11
Addressing the Overlooked11
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity11
JACC: CardioOncology11
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY11
Reply11
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT11
Clinical Practice Guidelines in Cardio-Oncology11
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer11
Reply10
Editorial Board/Officers Page10
Overcoming LGBTQI+ Disparities in Cardio-Oncology10
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy10
The Cause of Death in Patients With Cancer10
Full Issue PDF10
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA10
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies10
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population10
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB10
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN10
Reply9
The ESC Cardio-Oncology Guidelines9
Full Issue PDF9
Learning From Trials9
When Clot Is Tumor9
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients9
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients8
Reply8
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors8
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity8
Reply8
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma8
Editorial Board8
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage8
Assessing STEMI Outcomes in Patients With Cancer8
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION8
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients8
Cancer Diagnosis, Physical Activity, and Heart Disease Risk8
Reply8
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy8
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer8
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice8
0.16698002815247